Literature DB >> 26076048

Stigma from the Viewpoint of the Patient.

Joycelyn Sue Woods1, Herman Joseph.   

Abstract

Stigma has become a primary social force facing patients in methadone and buprenorphine treatment. For quality methadone and buprenorphine treatment to flourish it will be necessary to confront and reduce this negative influence. This article, co-authored by a patient and professional, discusses stigma and prejudice from the viewpoint of patients. Educational and national strategies using the media and targeted to patients, programs, and the general public are discussed.

Entities:  

Keywords:  Stigma; Stop Stigma Now; child welfare; criminal justice system; housing National Alliance for Medication Assisted Recovery; language; medical professionals

Mesh：

Substances：

Year:  2015        PMID： 26076048     DOI： 10.1080/10550887.2015.1059714

Source DB:  PubMed          Journal:  J Addict Dis        ISSN： 1055-0887


  11 in total

1.  Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.

Authors:  Michelle R Lofwall; Sharon L Walsh; Edward V Nunes; Genie L Bailey; Stacey C Sigmon; Kyle M Kampman; Michael Frost; Fredrik Tiberg; Margareta Linden; Behshad Sheldon; Sonia Oosman; Stefan Peterson; Michael Chen; Sonnie Kim
Journal:  JAMA Intern Med       Date:  2018-06-01       Impact factor: 21.873

2.  Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives.

Authors:  Kamilla L Venner; Dennis M Donovan; Aimee N C Campbell; Dennis C Wendt; Traci Rieckmann; Sandra M Radin; Sandra L Momper; Carmen L Rosa
Journal:  Addict Behav       Date:  2018-05-23       Impact factor: 3.913

3.  Buprenorphine and its formulations: a comprehensive review.

Authors:  Salomon Poliwoda; Nazir Noor; Jack S Jenkins; Cain W Stark; Mattie Steib; Jamal Hasoon; Giustino Varrassi; Ivan Urits; Omar Viswanath; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-08-20

4.  Buprenorphine Waiver Attitudes Among Primary Care Providers.

Authors:  Benjamin Lai; Ivana Croghan; Jon O Ebbert
Journal:  J Prim Care Community Health       Date:  2022 Jan-Dec

5.  De-Stigmatizing the Language of Addiction #429.

Authors:  J Janet Ho; Katie F Jones; Zachary Sager; Sarah Wakeman; Jessica S Merlin
Journal:  J Palliat Med       Date:  2022-01       Impact factor: 2.947

6.  "You are not clean until you're not on anything": Perceptions of medication-assisted treatment in rural Appalachia.

Authors:  Emma L Richard; Christine A Schalkoff; Hannah M Piscalko; Daniel L Brook; Adams L Sibley; Kathryn E Lancaster; William C Miller; Vivian F Go
Journal:  Int J Drug Policy       Date:  2020-03-12

7.  Recovery opioid overdose team (ROOT) pilot program evaluation: A community-wide post-overdose response strategy.

Authors:  Chin Hwa Gina Dahlem; Marci Scalera; Glynis Anderson; Melisa Tasker; Robert Ploutz-Snyder; Sean Esteban McCabe; Carol J Boyd
Journal:  Subst Abus       Date:  2020-12-07       Impact factor: 3.716

8.  Qualitative characterizations of misinformed disclosure reactions to medications for opioid use disorders and their consequences.

Authors:  Natalie M Brousseau; Heather Farmer; Allison Karpyn; Jean-Philippe Laurenceau; John F Kelly; Elizabeth C Hill; Valerie A Earnshaw
Journal:  J Subst Abuse Treat       Date:  2021-08-09

9.  Factors associated with obtaining employment among opioid use disorder patients enrolled in a therapeutic workplace intervention.

Authors:  August F Holtyn; Forrest Toegel; Matthew D Novak; Kenneth Silverman
Journal:  Drug Alcohol Depend       Date:  2021-07-21       Impact factor: 4.852

10.  "Don't Label Them as Addicts!" Student Pharmacists' Views on the Stigma Associated with Opioid use Disorder.

Authors:  Alina Cernasev; Kelsey D Frederick; Elizabeth A Hall; Michael P Veve; Kenneth C Hohmeier
Journal:  Innov Pharm       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.